. 2017 May 30;177(2):195–205. doi: 10.1530/EJE-16-0905
This work is licensed under a Table 1.
Patients baseline characteristics in the phase II study (FAS). Data are presented as mean ± s.d. or as n (%).
| PEG-rhGH 0.1 mg/kg/week (LD) | PEG-rhGH 0.2 mg/kg/week (HD) | Daily rhGH 0.25 mg/kg/week | P value | |
|---|---|---|---|---|
| n | 32 | 31 | 34 | |
| Chronological age (year) | 10.91 ± 3.31 | 11.75 ± 3.95 | 10.54 ± 4.05 | 0.4507b |
| BA (year) | ||||
| Male | 6.19 ± 2.20 | 7.65 ± 2.42 | 6.16 ± 2.51 | 0.0518b |
| Female | 5.51 ± 1.54 | 5.60 ± 1.50 | 4.81 ± 2.16 | 0.6046b |
| Sex, n (%) | 0.4907a | |||
| Male | 23 (71.88) | 25 (80.65) | 23 (67.65) | |
| Female | 9 (28.3) | 6 (19.35) | 11 (32.35) | |
| Weight (kg) | 20.50 ± 7.23 | 23.01 ± 7.01 | 20.18 ± 6.06 | 0.1947b |
| Height (cm) | 110.18 ± 12.84 | 116.45 ± 11.69 | 110.42 ± 14.59 | 0.1050b |
| MPH (cm) | 164.95 ± 8.53 | 167.32 ± 6.56 | 165.38 ± 6.74 | 0.3101b |
| HV (cm/year) | 2.58 ± 0.87 | 2.86 ± 0.80 | 2.70 ± 0.92 | 0.4468b |
| IGF1 SDS | −2.44 ± 0.50 | −2.13 ± 1.09 | −2.33 ± 0.81 | 0.3480b |
| HTSDS | −4.84 ± 1.59 | −4.50 ± 2.20 | −4.48 ± 1.48 | 0.6519b |
| Corrected HTSDS | −5.02 ± 1.86 | −4.62 ± 2.16 | −4.55 ± 1.77 | 0.5701b |
| Pituitary gland MRI, n (%) | 0.9721a | |||
| Normal | 16 (50.00) | 15 (48.39) | 16 (47.06) | |
| Abnormalc | 16 (50.00) | 16 (51.61) | 18 (52.94) | |
| IGHD/MPHD (n/n) | 29/3 | 27/4 | 30/4 | 0.9210b |
a
Differences between the two groups were compared using bidirectional Cochran-Mantel-Haenszel (CMH)-χ2 test. bDifferences among the three groups were compared using the t-test or the χ2 test. cPituitary hypoplasia.
BA, bone age; FAS: Full analysis set; HTSDS, height standard deviation score; HV, height velocity; IGF1, insulin-like growth factor-1; IGFBP-3, IGF-binding protein-3; IGHD, isolated growth hormone deficiency; MPH, mid-parental height; MPHD, multiple pituitary hormone deficiencies; MRI, magnetic resonance imaging.